Biogen (BIIB) and Eisai Announce FDA's 3-Month Extension of Review Period for BLA for Aducanumab
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/24/2024
- Wall St slips as higher yields offset upbeat corporate earnings
- Tesla touts acceleration of new models, but Q1 results fall short of estimates
- Boeing reports first revenue drop in 7 quarters as deliveries decline
- Oil settles lower as U.S. business activity cools, concerns over Middle East ease
- Yen on the brink, but Tesla pulls back
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Hasbro (HAS) brand strength sees earnings top expectations
- China acquired top-end Nvidia AI chips despite recent US ban- Reuters
- Wolfe Research Downgrades Warner Brothers Discovery (WBD) to Underperform, 'out of concern that an incipient advertising downturn put guidance at risk'
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
- Midday movers: Tesla, Li Auto and CNH Industrial fall; Salesforce rises
Biogen (BIIB) Reports FDA Approval of PLEGRIDY (peginterferon beta-1a) Intramuscular Administration for Multiple Sclerosis
February 1, 2021 7:33 AM ESTBiogen Inc. (NASDAQ: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has approved a new intramuscular (IM) injection route of administration for PLEGRIDY® (peginterferon beta-1a) for the treatment of relapsing forms of multiple sclerosis (MS). The new IM administration offers people living with relapsing MS the well-characterized efficacy and safety of PLEGRIDY with the potential for significantly reduced injection site reactions. This... More
Stifel Upgrades Biogen (BIIB) to Buy
January 29, 2021 8:48 AM ESTStifel analyst Paul Matteis upgraded Biogen (NASDAQ: BIIB) from Hold to Buy with a price target of $358.00 (from $258.00).
The analyst comments "Our initial reaction after the Aducanumab AdComm was that the path to FDA approval seems challenging. Since, Biogen management's... More
Biogen (BIIB) Climbs 12% Pre-Open
January 29, 2021 7:41 AM ESTBiogen (NASDAQ: BIIB) Climbs 12% Pre-Open
Earlier Biogen (BIIB) and Eisai Announce FDA's 3-Month Extension of Review Period for BLA for Aducanumab... More
